Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc logo
SUPN

Supernus Pharmaceuticals Inc (SUPN)

$35.290.23%

Live
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$34.92
Day's Range
$35.4
$24.95
52-Week Range
$36.08
1 month return1.27%
3 month return4.33%
1 year return15.63%
5 year return10.06%

Company Information

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy; Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy; APOKYN® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson's disease (PD); MYOBLOC® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults; and XADAGO® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD; SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations ("on-off" episodes) in PD; SPN-820 for treatment-resistant depression; and SPN-817 for the treatment of epilepsy.
OrganizationSupernus Pharmaceuticals Inc
Employees575
CEOMr. Jack A. Khattar
IndustryHealth Technology

Analyst Recommendation

based on 4 analysts ratings

Buy
75%
Buy
25%
Hold
0%
Sell

Based on 4 Wall street analysts offering stock ratings for Supernus Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 13.35%

Current

$35.29

Target

$40.0

Recommendation Trend

Based on 4 analyst

Current1M Ago3M Ago
Buy
3
8
8
Hold
1
2
2
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
1.9B
Book Value
$15.78
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.66
PE Ratio
52.79
PEG Ratio
1.47
Wall Street Target Price
40.0

Valuation

Trailing PE52.79
Forward PE20.16
Price/Book (mrq)
2.21
Enterprise Value
1.9B
Enterprise Value/Revenue
2.95
Enterprise Value/Ebitda
16.66

Technicals

Beta
0.94
50 Day MA
33.79
200 Day MA
31.32

Institutional Holdings

Vanguard Group Inc

10.4%

Armistice Capital, LLC

8.72%

Dimensional Fund Advisors, Inc.

4.2%

State Street Corporation

3.66%

GW&K Investment Management, LLC

3.53%

Loomis, Sayles & Company LP

2.98%

Discover more

Frequently Asked Questions

What is Supernus Pharmaceuticals Inc share price today?

Can Indians buy Supernus Pharmaceuticals Inc shares?

How can I buy Supernus Pharmaceuticals Inc shares from India?

Can Fractional shares of Supernus Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Supernus Pharmaceuticals Inc stocks?

What are today’s High and Low prices of Supernus Pharmaceuticals Inc?

What are today’s traded volumes of Supernus Pharmaceuticals Inc?

What is today’s market capitalisation of Supernus Pharmaceuticals Inc?

What is the 52 Week High and Low Range of Supernus Pharmaceuticals Inc?

How much percentage Supernus Pharmaceuticals Inc is down from its 52 Week High?

How much percentage Supernus Pharmaceuticals Inc is up from its 52 Week low?

What are the historical returns of Supernus Pharmaceuticals Inc?

Who is the Chief Executive Officer (CEO) of Supernus Pharmaceuticals Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*